Aytu Biopharma Inc (AYTU) Stock Price, Quote & News

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 720 437 6580

Website: aytubio.com

Address:

Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States

inv1ncible Mar. 20 at 4:48 AM

$AYTU

0 · Reply

Lucas76 Mar. 19 at 9:34 PM

$AYTU Now that's impressive:

0 · Reply

termoil Mar. 18 at 3:58 PM

$AYTU If the board decides to sell then what would be a fair price per share?

1 · Reply

YourObscureCEOforLife Mar. 17 at 8:51 PM

$AYTU

0 · Reply

Alain_Simard Mar. 13 at 1:56 PM

$AYTU the only thing that $AYTU has going for it is that it doesn’t have any Iran exposure

0 · Reply

Love_To_Learn Mar. 11 at 8:47 PM

$CDXS 1.8 key now old beloved sending code now also main 1.8 key creator $AYTU executing !

1 · Reply

mfoxx Mar. 11 at 5:29 PM

$AYTU when delist?

0 · Reply

Love_To_Learn Mar. 11 at 1:09 PM

$AYTU $SIDU $BDRX MAKING CHANGES TO ALL 3 OF U

0 · Reply

MadryKielbasa Mar. 9 at 4:54 PM

$AYTU

1 · Reply

BillionerOfKing Feb. 27 at 11:55 PM

$AYTU Current Stock Price: $2.57

0 · Reply

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Jan 27, 2026, 4:05 PM EST - 7 weeks ago

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Jan 20, 2026, 4:05 PM EST - 2 months ago

Aytu BioPharma Recaps Investor Day Held on January 20, 2026

Jan 13, 2026, 4:15 PM EST - 2 months ago

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Jan 12, 2026, 8:00 AM EST - 2 months ago

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Dec 18, 2025, 9:00 AM EST - 3 months ago

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

Dec 15, 2025, 9:00 AM EST - 3 months ago

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Nov 24, 2025, 4:05 PM EST - 4 months ago

Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 13, 2025, 4:05 PM EST - 4 months ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025, 4:05 PM EST - 4 months ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Oct 28, 2025, 9:00 AM EDT - 5 months ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 10, 2025, 9:00 AM EDT - 5 months ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Sep 24, 2025, 4:15 PM EDT - 6 months ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

Sep 23, 2025, 4:05 PM EDT - 6 months ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025, 4:05 PM EDT - 6 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 9, 2025, 4:30 PM EDT - 10 months ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

Jun 6, 2025, 8:01 AM EDT - 10 months ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:00 AM EDT - 10 months ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

May 14, 2025, 4:05 PM EDT - 11 months ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025, 4:15 PM EDT - 11 months ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 21, 2025, 4:05 PM EDT - 11 months ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Feb 12, 2025, 4:03 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 5, 2025, 5:50 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025, 9:00 AM EST - 1 year ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

May 15, 2024, 4:05 PM EDT - 2 years ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 8, 2024, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 7, 2024, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Jan 23, 2024, 9:00 AM EST - 2 years ago

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Nov 30, 2023, 8:00 AM EST - 2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 8, 2023, 8:30 AM EST - 2 years ago

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 7, 2023, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Oct 9, 2023, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Sep 27, 2023, 4:20 PM EDT - 2 years ago

Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023

inv1ncible Mar. 20 at 4:48 AM

$AYTU

0 · Reply

Lucas76 Mar. 19 at 9:34 PM

$AYTU Now that's impressive:

0 · Reply

termoil Mar. 18 at 3:58 PM

$AYTU If the board decides to sell then what would be a fair price per share?

1 · Reply

YourObscureCEOforLife Mar. 17 at 8:51 PM

$AYTU

0 · Reply

Alain_Simard Mar. 13 at 1:56 PM

$AYTU the only thing that $AYTU has going for it is that it doesn’t have any Iran exposure

0 · Reply

Love_To_Learn Mar. 11 at 8:47 PM

$CDXS 1.8 key now old beloved sending code now also main 1.8 key creator $AYTU executing !

1 · Reply

mfoxx Mar. 11 at 5:29 PM

$AYTU when delist?

0 · Reply

Love_To_Learn Mar. 11 at 1:09 PM

$AYTU $SIDU $BDRX MAKING CHANGES TO ALL 3 OF U

0 · Reply

MadryKielbasa Mar. 9 at 4:54 PM

$AYTU

1 · Reply

BillionerOfKing Feb. 27 at 11:55 PM

$AYTU Current Stock Price: $2.57

0 · Reply

OfficialStocktwitsUser Feb. 26 at 7:15 PM

$AYTU RSI: 61.90, MACD: -0.0554 Vol: 0.16, MA20: 2.36, MA50: 2.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Pocahonta Feb. 25 at 9:51 PM

$AYTU Dishbrow ain’t in jail yet? Still Trading and deceiving Investors? Where are the FEDS???

0 · Reply

Framingtheworld Feb. 23 at 7:48 AM

$AYTU $ATAI has far better product

0 · Reply

Dolphinsarecute Feb. 18 at 7:28 PM

$AYTU Remember that there's a tomorrow tomorrow as well! Moonshot! Give this guy a follow if you've got too much money sitting around!

3 · Reply

HiPlainsTrader Feb. 18 at 1:54 PM

$AYTU where’s my light!?

0 · Reply

PortfolioQuintessence Feb. 17 at 1:15 PM

$AYTU Pre-revenue biotech; early-stage.

2 · Reply

TradeNiko Feb. 17 at 8:50 AM

$AYTU Pre-revenue biotech; early-stage

0 · Reply

BillionerOfKing Feb. 13 at 2:54 AM

$AYTU Current Stock Price: $2.18

0 · Reply

CodeCatalyst Feb. 9 at 3:14 PM

$AYTU Biotech with diversified therapeutic focus; resources are spread thin.

0 · Reply

Fffrre321 Feb. 6 at 3:13 PM

$AYTU Trumprx is on. Exua meets Trump's requirements. 1. Manufacturing plants in the U.S. 2. Cheap prices 3. Self-platforms 4. First depressive drug with less side effects AYTU must actively participate in TrumpRX to increase the number of prescriptions and have a marketing opportunity to promote new drugs to patients. Signing with the government with news of the release of new drugs could have huge long-term benefits. This is a huge social issue in the U.S. aaytu is a fool if you miss this opportunity

1 · Reply

Dolphinsarecute Feb. 4 at 8:45 PM

$AYTU I recommend you go all in. Can't get a more serious company, CEO OR stock! Buy all you can, this is going to at least 20, yesterday AH!!!!!

1 · Reply

Henry20feb_ Feb. 4 at 3:06 PM

$AYTU This is more “steady specialty pharma with an upside catalyst” than “binary biotech moonshot.” If EXXUA ramps, EBITDA likely flips positive fast. If not, downside seems cushioned by the existing $15M/quarter base. Next 2–3 quarters = all about EXXUA scripts, not GAAP net loss noise!

1 · Reply

Market Cap	28.01M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.43%
Debt to Equity Ratio	1.47

Volume	80,000
Avg Vol	69,336
Day's Range	N/A - N/A
Shares Out	10.73M
Stochastic %K	57%
Beta	0.35
Analysts	Strong Sell
Price Target	$9.67